SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MGT Capital Investments, Inc. of Class Action Lawsuit and Upcoming Deadline – MGT

NEW YORK, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against MGT Capital Investments, Inc. (“MGT” or the “Company”) (NYSE: MGT ) and certain of its officers.   The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-07449, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired MGT securities between May 9, 2016 and September 20, 2016 both dates inclusive (the “Class Period”).  This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). 

If you are a shareholder who purchased MGT securities during the Class Period, you have until November 21, 2016 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 

[Click here to join this class action]

MGT, together with its subsidiaries, purports to acquire, develop, and monetize assets in the online, mobile, and casino gaming space. The Company operates through two segments, Gaming and Intellectual Property.

On May 9, 2016, MGT announced that it had entered into a definitive asset purchase agreement to acquire certain assets and technology from D-Vasive Inc. (“D-Vasive”), a provider of anti-spy software (the “D-Vasive Transaction”).  In conjunction with the transaction, MGT announced the proposed appointment of Defendant John McAfee (“McAfee”) as the Company’s Executive Chairman and Chief Executive Officer (“CEO”), and that the Company intended to change its corporate name to John McAfee Global Technologies, Inc.  MGT further advised investors that “[m]ajor terms of the deal include the payment to D-Vasive Inc. stockholders of 23.8 million restricted shares of MGT stock and $300,000 in cash.  The proposed share issuance is expected to amount to roughly 47% of the Company on a pro-forma diluted basis at closing.”

On May 26, 2016, MGT announced that it had entered into a definitive asset purchase agreement to acquire certain technology and assets from Demonsaw LLC (“Demonsaw”), which the Company touted as “a provider of a secure and anonymous file sharing software platform.”  MGT further advised investors that “[m]ajor terms of the deal include the payment to Demonsaw LLC members of 20.0 million restricted shares of MGT common stock.  The proposed share issuance is expected to amount to approximately 28% of the Company’s common stock on a pro-forma fully diluted basis at closing, inclusive of shares of common stock to be issued in connection with the Company’s previously announced transaction with D-Vasive, Inc.”  The Company and D-Vasive would subsequently arrange for D-Vasive to purchase Demonsaw in advance of the D-Vasive Transaction, “in order to simplify these transactions, and meet certain customary tax issues,” so that MGT would acquire Demonsaw’s assets as well as D-Vasive’s via the D-Vasive Transaction.

On September 9, 2016, MGT announced that at the Company’s 2016 Annual Meeting of Stockholders, its stockholders had approved, inter alia , the issuance of a total of 43.8 million shares of common stock in connection with the D-Vasive Transaction.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) the NYSE was unlikely to approve the listing of the 43.8 million additional shares that the Company was required to issue to consummate the D-Vasive Transaction; and (ii) as a result of the foregoing, MGT’s public statements were materially false and misleading at all relevant times. 

On September 19, 2016, pre-market, MGT announced that on September 15, 2016, the Company received a subpoena from the U.S. Securities and Exchange Commission (“SEC”) requesting certain information from the Company.  MGT stated that it had no reason to believe that the Company is or will be the subject of any enforcement proceedings and was fully cooperating to comply with the SEC’s request. 

On this news, MGT stock fell $0.74, or 22.7%, to close at $2.52 on September 19, 2016.

Then, on September 20, 2016, pre-market, MGT announced that the NYSE had informed the Company on September 19, 2016 that it would “not approve the listing on the Exchange of the 43.8 million shares that the Company is required to issue in order to complete the closing of the D-Vasive [sic] merger,” and that “[t]he Company and John McAfee remain committed to closing the transaction and are exploring alternatives.”

On this news, MGT stock fell $0.63, or 25%, to close at $1.89 on September 20, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

 

CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 13

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 8

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 10

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 6

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 11

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 13

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Credit Card Interest Rates and How to Manage Them

Updated Category News Views 352

Understanding Credit Card Interest Rates Recently, the average credit card interest rate has climbed to 22.63%, a notable rise from the previous average of 16.98%. The interest rate you face can vary widely based on the type of credit card and your individual credit profile. By understanding how credit card annual percentage rates (APR) work, you can potentially reduce...

Continue Reading
Hexaware Reports Strong Q3CY25 Performance with Revenue Rise

Updated Category News Views 183

Hexaware Technologies Financial Results Overview Hexaware Technologies (NSE: HEXT) has showcased impressive performance for the third quarter of calendar year 2025, with total revenue reaching USD 394.8 million. This figure marks a noteworthy increase of 5.5% year-over-year, showcasing the company's resilience and ability to navigate market challenges effectively....

Continue Reading
Alm. Brand A/S Reports Progress in Share Buybacks for 2024

Updated Category News Views 102

Overview of Alm. Brand A/S Share Buy-Back Program Alm. Brand A/S has kicked off an ambitious share buy-back program, looking to acquire shares totaling up to DKK 150 million. This initiative was officially announced earlier, providing insight into the year's financial strategy. Recent Transactions Under the Program During the week starting 9 September 2024 and ending on...

Continue Reading
NRx Pharmaceuticals Adjusts Release Date for Q2 Financials

Updated Category News Views 158

NRx Pharmaceuticals Announces Rescheduled Q2 2025 Financial Results Release NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) recently made an exciting announcement regarding the release of its second quarter 2025 financial results. The company has decided to delay the publication of these results to ensure a more comprehensive presentation for its stakeholders. This update comes...

Continue Reading
Top 5 Stocks to Watch for a Market Pullback Soon

Updated Category News Views 216

Understanding Market Pullbacks As major U.S. stock indices reached unprecedented levels recently, the optimism surrounding potential Federal Reserve rate cuts has driven prices higher. However, the surge seems excessive given the realistically anticipated modest decrease in rates. This opens a window for investors to reassess their portfolios, particularly those holdings...

Continue Reading